Get the Stockscreener App
0.823
1.32%
-0.011
After Hours:
.83
0.007
+0.85%
Atossa Therapeutics Inc stock is traded at $0.823, with a volume of 684.64K.
It is down -1.32% in the last 24 hours and down -0.15% over the past month.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
See More
Previous Close:
$0.834
Open:
$0.834
24h Volume:
684.64K
Relative Volume:
0.60
Market Cap:
$106.31M
Revenue:
-
Net Income/Loss:
$-26.91M
P/E Ratio:
-3.7409
EPS:
-0.22
Net Cash Flow:
$-19.57M
1W Performance:
-2.01%
1M Performance:
-0.15%
6M Performance:
-2.24%
1Y Performance:
-36.20%
1-Day Range:
$0.81
$0.85
1-Week Range:
$0.81
$0.984
52-Week Range:
$0.5526
$1.66
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Name
Atossa Therapeutics Inc
Sector
Industry
Phone
206.588.0256
Address
10202 5TH AVENUE NE, SEATTLE, WA
Compare ATOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.823 | 107.73M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-18 | Initiated | Maxim Group | Buy |
Atossa Therapeutics Inc Stock (ATOS) Latest News
How does Atossa Therapeutics Inc. generate profit in a changing economyStock Market Data Feed For Consistent Profits - jammulinksnews.com
Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Joplin Globe
Applying sector rotation models to Atossa Therapeutics Inc.Daily Market Momentum Summary and Strategy - Newser
Atossa Therapeutics Inc. stock momentum explainedMomentum Stocks with Breakout Potential - Newser
What recovery options are there for Atossa Therapeutics Inc.Smart Safety Strategy With Real Data Analysis - Newser
Is Atossa Therapeutics Inc. a growth stock or a value stockRetirement Planning Updates For Consistent Profits - jammulinksnews.com
What are Atossa Therapeutics Inc. company’s key revenue driversAI Powered Entry Points From AI Tools - jammulinksnews.com
Leading vs lagging indicators on Atossa Therapeutics Inc. performanceHigh Return Trade Roadmap with Setup Filters - Newser
What the charts say about Atossa Therapeutics Inc. todayChart Risk Profile for Capital Preservation - Newser
Is Atossa Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideMomentum Detection with Entry Optimization - Newser
Atossa Therapeutics Shares Surge 13.14% on FDA Validation of (Z)-Endoxifen Strategy - AInvest
Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer - BioSpace
Identifying reversal signals in Atossa Therapeutics Inc.Weekly Growth Portfolio Performance Summary - Newser
Why Atossa Therapeutics Inc. stock attracts strong analyst attentionWeekly High Conviction Trade Setup Analysis - Newser
Atossa Therapeutics stock jumps after FDA provides positive feedback By Investing.com - Investing.com Canada
Atossa Therapeutics stock jumps after FDA provides positive feedback - Investing.com
FDA Green Lights Atossa's Novel Breast Cancer Drug Strategy: Key Development Milestones Revealed - Stock Titan
Will Atossa Therapeutics Inc. benefit from macro trendsReal-Time Signal Tracking with Entry Level - Newser
How volatile is Atossa Therapeutics Inc. stock compared to the marketFree Investment Portfolio Suggestions - jammulinksnews.com
What catalysts could drive Atossa Therapeutics Inc. stock higher in 2025Advanced Screener Planner For Consistent Profits - jammulinksnews.com
Multi asset correlation models including Atossa Therapeutics Inc.Free Fundamental Growth Stock Analysis - Newser
When is Atossa Therapeutics Inc. stock expected to show significant growthAccelerated profit realization - jammulinksnews.com
What is Atossa Therapeutics Inc. company’s growth strategyReal Time Watchlist With Proven Results - jammulinksnews.com
What makes Atossa Therapeutics Inc. stock price move sharplyGet alerts on the hottest market movers - jammulinksnews.com
How does Atossa Therapeutics Inc. compare to its industry peersGet timely alerts on market movers - jammulinksnews.com
New Product Launches: Will They Boost Atossa Therapeutics Inc. Stock in 2025ROI Driven Alerts - Newser
Is Atossa Therapeutics Inc. a good long term investmentHigh-impact investment strategies - PrintWeekIndia
Atossa Therapeutics Inc. Stock Analysis and ForecastHigh-performance investment picks - PrintWeekIndia
What analysts say about Atossa Therapeutics Inc. stockFree Market Volatility Navigation Tips - Autocar Professional
Does Atossa Therapeutics Inc. stock pay reliable dividendsPowerful profit generation - jammulinksnews.com
What drives Atossa Therapeutics Inc. stock priceDynamic investment opportunities - PrintWeekIndia
Will Atossa Therapeutics Inc. stock split in the near futureDynamic investment growth - jammulinksnews.com
How Atossa Therapeutics Inc. stock reacts to Fed policy changesStrongest growth potential - jammulinksnews.com
Atossa Therapeutics Inc Stock (ATOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atossa Therapeutics Inc Stock (ATOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Remmel H. Lawrence | Director |
Mar 26 '25 |
Buy |
0.70 |
10,000 |
7,000 |
10,257 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):